Anaemia is a common consequence of chronic kidney disease (CKD); however, the risk factors for its development and impact on outcomes have not been well synthesised. Therefore, we undertook systematic review to fully characterise associated with presence anaemia in patients CKD contemporary synthesis risks adverse anaemia. We searched MEDLINE, EMBASE, Cochrane Library from 2002 until 2018 studies reporting incidence or prevalence and/or associations between haemoglobin (Hb) mortality, major...

At present, the clinical burden of hypokalaemia and hyperkalaemia among European heart failure patients, relationships between serum potassium adverse outcomes in this population, is not well characterized. The aim study was to investigate associations mortality, major cardiac events, renin-angiotensin-aldosterone system inhibitor (RAASi) discontinuation across levels, a UK cohort incident patients.This retrospective observational newly diagnosed patients listed Clinical Practice Research...

To address a current paucity of European data, this study developed equations to predict risks mortality, major adverse cardiac events (MACE) and renin angiotensin-aldosterone system inhibitor (RAASi) discontinuation using time-varying serum potassium other covariates, in UK cohort chronic kidney disease (CKD) patients.This was retrospective observational adult CKD patients listed on the Clinical Practice Research Datalink, with first record (stage 3a-5, pre-dialysis) between 2006 2015....

People with chronic kidney disease (CKD) are at an increased risk of developing hyperkalaemia due to their declining function. In addition, these patients often required reduce or discontinue guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAASi) therapy hyperkalaemia. This original research developed a model quantify the health and economic benefits maintaining normokalaemia enabling optimal RAASi in CKD. A patient-level simulation was designed fully characterise...

Understanding predictors and trajectories of increased potassium may inform testing treatment hyperkalemia. We examined for repeated hyperkalemia among patients after first-time renin angiotensin system inhibitor (RASi) prescription, chronic kidney disease (CKD), or heart failure (CHF); we also in these their first event. used Danish population-based registries to identify all with RASi incident CKD, CHF (2000–2012). For a event, over the following 6 months were examined. The associated...

To investigate healthcare costs associated with hyperkalaemia (HK) among patients chronic kidney disease (CKD), heart failure (HF) or diabetes. Before-after cohort study of HK and matched without HK. Population-based databases covering primary secondary care for the entire Northern Denmark. Patients a first incident record CKD (n=78 372), HF (n=14 233) diabetes (n=37 479) during 2005-2011. Among all experiencing event (potassium level >5.0 mmol/L), were compared 6 months before after event....

Abstract Aims To examine the incidence, risk factors and clinical outcomes of hyperkalaemia in people with diabetes a real‐world setting. Methods Using Danish health registries, we identified population‐based cohort first‐time drug‐treated diabetes, period 2000−2012. First, cumulative incidence hyperkalaemia, defined as first blood test potassium level >5.0 mmol/l after treatment initiation, was ascertained. Second, case–control analysis, were compared vs without hyperkalaemia. Third,...

Anemia in chronic kidney disease (CKD) is associated with reduced health-related quality of life and physical functioning. This study investigated knowledge awareness anemia patients CKD the United States (US) through an online, quantitative survey administered to aged ≥18 years self-reported CKD, or without anemia. Of 446 included, 255 (57.2%) were diagnosed 191 (42.8%) non-anemia cohort. In anemia, 71.0% aware relationship between versus 52.9% cohort, 46.3% their hemoglobin level, 27.2%...

Patients with heart failure are at increased risk of hyperkalemia, particularly when treated renin-angiotensin-aldosterone system inhibitor (RAASi) agents. This study developed a model to quantify the potential health and economic value associated sustained potassium management optimal RAASi therapy in patients.A patient-level, fixed-time increment stochastic simulation was designed characterize progression through New York Heart Association functional classes, predict associations between...

We explored the association of anemia severity in patients with chronic kidney disease (CKD) and treatment work productivity China.Cross-sectional survey data from Chinese physicians their CKD were collected 2015. Physicians recorded demographics, characteristics, treatment. Patients completed Work Productivity Activity Impairment questionnaire. Data stratified by dialysis-dependence, hemoglobin (Hb) level, treatment.Based on 1,052 (704 non-dialysis-dependent [NDD] 348 dialysis-dependent...

Background Chronic kidney disease patients have impaired health-related quality of life and an increased risk hyperkalaemia. Aims The objective was to evaluate the impact hyperkalaemia on life, investigate lifestyle change recommendations, in these patients. Methods Adelphi Real World Kidney Disease Specific Programme™ used. Data were collected from physicians with non-dialysis dependent stage 3a, 3b 4 chronic US, France, Germany, Spain, Italy, UK China. Patients completed Quality Life...

Background: Anemia is a common complication of chronic kidney disease (CKD) that may reduce patients' health-related quality life (HRQoL). This study explored the experience and knowledge patients with CKD, without anemia, in China. Methods: A quantitative online survey was administered to 500 consenting Chinese patient volunteers aged ≥ 18 years self-reported or between August 29, September 17, 2018. Patients cancer were excluded. The 27-question HRQoL, anemia management, interactions...

INTRODUCTION AND AIMS:The UK Renal Registry (UKRR) and Kidney Care UK's (KCUK) Chronic Disease Patient Reported Experience Measure (CKDPREM) was developed by patients, academics clinicians in 2016.The CKDPREM designed to provide clinical directors with information about their services from the user perspective, inform quality improvement initiatives contribute research.Following a pilot of over 8,000 patients 2016, subsequent

Hyperkalaemia (HK) is associated with increased risk of mortality. Renin-angiotensin-aldosterone system inhibitors (RAASi) can reduce mortality and slow disease progression in heart failure (HF) chronic kidney (CKD); however, their use may be limited by potential to cause HK. This study aimed quantify the relationship between elevated serum potassium (K+) levels RAASi discontinuation HF CKD. Poisson Generalized Estimating Equations, derived from time-updated K+ data 23,541 144,388 CKD...

Hyperkalaemia (HK) is associated with increased risk of mortality. This study aimed to develop a prediction tool assess the probability mortality in patients heart failure (HF) or chronic kidney disease (CKD) at HK, based on relevant demographics and clinical factors. Poisson Generalized Estimating Equations fitted 23,541 HF 144,388 CKD Clinical Practice Research Datalink (Jan 2006–Dec 2015) were incorporated within an Excel-based predict annual probabilities using demographic, comorbidity,...

level (mmol/l) 7.